<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; opposition</title>
	<atom:link href="http://www.tapanray.in/tag/opposition/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
